Pharmacological treatments of COVID-19.
Pharmacol Rep
; 72(6): 1446-1478, 2020 Dec.
Статья
в английский
| MEDLINE | ID: covidwho-2060162
ABSTRACT
The viral infection due to the new coronavirus or coronavirus disease 2019 (COVID-19), which was reported for the first time in December 2019, was named by the World Health Organization (WHO) as Severe Acute Respiratory Syndrome-Coronavirus-2 (SARS-CoV2), because of the very similar genome and also its related symptoms to SARS-CoV1. The ongoing COVID-19 pandemic with significant mortality, morbidity, and socioeconomic impact is considered by the WHO as a global public health emergency. Since there is no specific treatment available for SARS-CoV2 infection, and or COVID-19, several clinical and sub-clinical studies are currently undertaken to find a gold-standard therapeutic regimen with high efficacy and low side effect. Based on the published scientific evidence published to date, we summarized herein the effects of different potential therapies and up-to-date clinical trials. The review is intended to help readers aware of potentially effective COVID-19 treatment and provide useful references for future studies.
ключевые слова
Полный текст:
Имеется в наличии
Коллекция:
Международные базы данных
база данных:
MEDLINE
Основная тема:
SARS-CoV-2
/
COVID-19 Drug Treatment
Тип исследования:
Прогностическое исследование
/
Рандомизированные контролируемые испытания
Пределы темы:
Животные
/
Люди
Язык:
английский
Журнал:
Pharmacol Rep
Тематика журнала:
Фармакология
Год:
2020
Тип:
Статья
Аффилированная страна:
S43440-020-00152-9
Документы, близкие по теме
MEDLINE
...
LILACS
LIS